4-hydroxycyclophosphamide has been researched along with Uterine Cervical Neoplasms in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bai, T; Tanaka, T; Umesaki, N; Utsunomiya, T; Yukawa, K | 1 |
1 other study(ies) available for 4-hydroxycyclophosphamide and Uterine Cervical Neoplasms
| Article | Year |
|---|---|
Reduced radiosensitivity and increased CD40 expression in cyclophosphamide-resistant subclones established from human cervical squamous cell carcinoma cells.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Bleomycin; Carcinoma, Squamous Cell; CD40 Antigens; CD40 Ligand; CD59 Antigens; Cell Line, Tumor; Cell Proliferation; Cyclophosphamide; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Flow Cytometry; Gamma Rays; Humans; Integrin alpha1; Integrin alpha2; Integrin alpha3; Integrin alpha4; Integrin alpha5; Integrin alpha6; Integrin beta1; Radiation Tolerance; Uterine Cervical Neoplasms | 2005 |